Chris Cameron

18PUBLICATIONS
29CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Respiratory diseasesMedical virologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jan 06, 2025
Correction to: Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.

Ataru Igarashi, Shiro Tanaka, Raf De Moor

|Nov 12, 2024
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.

Ataru Igarashi, Shiro Tanaka, Raf De Moor

|Apr 28, 2023
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant.

Ernest H Law, Chris Cameron

|Jan 06, 2023
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.

Rena Buckstein, Lisa Chodirker, Karen W L Yee

|Sep 12, 2022
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.

Rena Buckstein, Lisa Chodirker, Lee Mozessohn

|Nov 09, 2021
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.

Ernest Law, Roya Gavanji, Sarah Walsh

Pageof 3

Frequent Collaborators

7 joint publications

Imtiaz A Samjoo

6 joint publications

Evelyn Worthington

6 joint publications

Anja Haltner

4 joint publications

Christopher Drudge